{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:12:02Z","timestamp":1781925122645,"version":"3.54.5"},"reference-count":92,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1053\/j.semnuclmed.2021.04.002","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T19:16:30Z","timestamp":1620760590000},"page":"458-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["\u201cPET\/CT Variants and Pitfalls in Lung Cancer and Mesothelioma\u201d"],"prefix":"10.1053","volume":"51","author":[{"given":"Egesta","family":"Lopci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopinath","family":"Gnanasegaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit A.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lioe-Fee","family":"de Geus-Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl_4","key":"10.1053\/j.semnuclmed.2021.04.002_bib0001","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0002","series-title":"SEER Cancer Statistics Review, 1975-2016, based on November SEER data submission, posted to the SEER web site, Aprile 2019","author":"Howlader","year":"2019"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0003","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"5 Suppl","key":"10.1053\/j.semnuclmed.2021.04.002_bib0004","doi-asserted-by":"crossref","first-page":"e121S","DOI":"10.1378\/chest.12-2352","article-title":"Clinical and organizational factors in the initial evaluation of patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Ost","year":"2013","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0005","series-title":"Diseases of the Chest, Breast, Heart and Vessels 2019-2022: Diagnostic and Interventional Imaging [Internet]","article-title":"Current concepts in the diagnosis and staging of lung cancer. 019 Feb 20","author":"Carter","year":"2019"},{"issue":"Suppl 5","key":"10.1053\/j.semnuclmed.2021.04.002_bib0006","doi-asserted-by":"crossref","first-page":"S568","DOI":"10.21037\/tcr.2018.04.10","article-title":"Non-small cell lung carcinoma: understanding cancer microenvironment to drive immunotherapy and patients selection","volume":"7","author":"Castello","year":"2018","journal-title":"Transl Cancer Res"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001764","article-title":"Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts","volume":"11","author":"Tammemagi","year":"2014","journal-title":"PLoS Med;"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0008","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.285.7.914","article-title":"Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis","volume":"285","author":"Gould","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0009","first-page":"1412","article-title":"Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes","volume":"42","author":"Zhuang","year":"2001","journal-title":"J Nucl Med;"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0010","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(02)08352-6","article-title":"Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial","volume":"359","author":"van Tinteren","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0011","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1148\/rg.2018180060","article-title":"Role of FDG PET\/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer","volume":"38","author":"Kandathil","year":"2018","journal-title":"Radiographics"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0012","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cllc.2011.08.002","article-title":"Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis","volume":"13","author":"Wang","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0013","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.suronc.2013.04.001","article-title":"Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients","volume":"22","author":"Li-2013","year":"2013","journal-title":"Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0014","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3892\/mco.2014.410","article-title":"Specific organ metastases and survival in metastatic non-small-cell lung cancer","volume":"3","author":"Tamura","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0015","doi-asserted-by":"crossref","first-page":"35743","DOI":"10.18632\/oncotarget.16182","article-title":"Comparison of gadolinium-enhanced MRI and 18FDG PET\/PET-CT for the diagnosis of brain metastases in lung cancer patients: a meta-analysis of 5 prospective studies","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0016","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2214\/AJR.19.22571","article-title":"The role of dual-phase FDG PET\/CT in the diagnosis and follow-up of brain tumors","volume":"215","author":"Ozutemiz","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0017","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1007\/s00330-014-3362-z","article-title":"Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer","volume":"24","author":"Grootjans","year":"2014","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0018","doi-asserted-by":"crossref","first-page":"e98033","DOI":"10.1371\/journal.pone.0098033","article-title":"Respiratory motion reduction in PET\/CT using abdominal compression for lung cancer patients","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0019","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/mp.12651","article-title":"Data-driven optimal binning for respiratory motion management in PET","volume":"45","author":"Kesner","year":"2018","journal-title":"Med Phys"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0020","first-page":"5249","article-title":"Respiratory Motion Correction Using A Novel Positron Emission Particle Tracking Technique: A Framework Towards Individual Lesion-Based Motion Correction","author":"Tumpa","year":"2018","journal-title":"Conf Proc IEEE Eng Med Biol Soc"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170774","article-title":"Evidence-based management of incidental focal uptake of fluorodeoxyglucose on PET-CT","volume":"91","author":"Pencharz","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0022","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2967\/jnumed.106.035774","article-title":"Partial-volume effect in PET tumor imaging","volume":"48","author":"Soret","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0023","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2967\/jnumed.117.191171","article-title":"Metal Artifact Reduction of CT Scans to Improve PET\/CT","volume":"58","author":"van der Vos","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0024","first-page":"1267","article-title":"\u201cUSA-Fat\u201d: prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET\/CT","volume":"44","author":"Cohade","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0025","first-page":"145","article-title":"18F-FDG imaging: pitfalls and artifacts","volume":"33","author":"Abouzied","year":"2005","journal-title":"J Nucl Med Technol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0026","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1148\/radiol.2241011254","article-title":"Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion \u2013 report of six cases","volume":"224","author":"Kamel","year":"2002","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0027","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1148\/rg.246045701","article-title":"Spectrum of thymic uptake at 18F-FDG PET","volume":"24","author":"Ferdinand","year":"2004","journal-title":"Radiographics"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0028","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00005382-200605000-00003","article-title":"Pitfalls in integrated CT-PET of the thorax: implications in oncologic imaging","volume":"21","author":"Truong","year":"2006","journal-title":"J Thorac Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2021.04.002_bib0029","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2214\/AJR.19.21227","article-title":"Lung cancer recurrence: 18 F-FDG PET\/CT in Clinical Practice","volume":"213","author":"Kandathil","year":"2019","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2021.04.002_bib0030","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/icvts\/ivs368","article-title":"18F-fluorodeoxyglucose positron emission tomography\/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients","volume":"15","author":"Toba","year":"2012","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0031","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00330-011-2299-8","article-title":"Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria","volume":"22","author":"Caulo","year":"2012","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0032","first-page":"146","article-title":"Recurrence of lung cancer after radiofrequency ablation detected by PET\/CT and contrast enhanced CT scan","volume":"95","author":"Scappaticci","year":"2012","journal-title":"Med Health R I"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0033","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cllc.2020.06.020","article-title":"Imaging in therapy response assessment and surveillance of lung cancer: evidenced-based review with focus on the utility of 18 F-FDG PET\/CT","volume":"21","author":"Sheikhbahaei","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0034","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1097\/JTO.0000000000000618","article-title":"Prognostic factors of survival after recurrence in patients with resected lung adenocarcinoma","volume":"10","author":"Hung","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0035","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1470-2045(12)70242-5","article-title":"Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis","volume":"13","author":"Senthi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0036","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1378\/chest.125.6.2356","article-title":"Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis","volume":"125","author":"Kwek","year":"2004","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0037","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cllc.2014.07.001","article-title":"Metachronous and synchronous primary lung cancers: diagnostic aspects, surgical treatment, and prognosis","volume":"16","author":"Loukeri","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0038","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.ro.2013.03.017","article-title":"Malignant pleural mesothelioma: role of CT, MRI, and PET\/CT in staging evaluation and treatment considerations","volume":"48","author":"Troung","year":"2013","journal-title":"Semin Roentgenol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0039","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2559.1997.5460776.x","article-title":"Pathology of malignant mesothelioma","volume":"30","author":"Attanoos","year":"1997","journal-title":"Histopathology"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02306613","article-title":"Surgically debulked malignant pleural mesothelioma: Results and prognostic factors","volume":"4","author":"Pass","year":"1997","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0041","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5","article-title":"Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients Part 2: Prognosis and staging","volume":"72","author":"Boutin","year":"1993","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0042","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0043","first-page":"1","article-title":"Immune checkpoint inhibitor for treatment of mesothelioma","volume":"2","author":"Novak","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0044","series-title":"Atlas of Response to Immunotherapy","year":"2020"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0045","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0046","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0047","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/RCT.0000000000000174","article-title":"Use of computed tomography and positron emission tomography\/computed tomography for staging of local extent in patients with malignant pleural mesothelioma","volume":"39","author":"Frauenfelder","year":"2015","journal-title":"J Comput Assist Tomogr"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0048","first-page":"111","article-title":"Additional value of hybrid PET\/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma","volume":"8","author":"Ambrosini","year":"2005","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0049","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.107.042333","article-title":"Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans","volume":"48","author":"Francis","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.lungcan.2009.04.015","article-title":"Combined FDG-PET\/CT in response evaluation of malignant pleural mesothelioma","volume":"67","author":"Veit-Haibach","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0051","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.ejrad.2010.11.006","article-title":"Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDGPET\/CT","volume":"81","author":"Schaefer","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0052","article-title":"Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET\/CT scan in patients with malignant pleural mesothelioma","volume":"18","author":"Lim","year":"2020","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0053","first-page":"127","article-title":"Clinical staging of malignant pleural mesothelioma: current perspectives","volume":"8","author":"Bonomi","year":"2017","journal-title":"Lung Cancer: Targets and Therapy"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0054","first-page":"1144","article-title":"Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology","volume":"43","author":"Gerbaudo","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0055","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00006231-200306000-00001","article-title":"18F-FDG imaging of malignant pleural mesothelioma: scientiam impendere vero","volume":"24","author":"Gerbaudo","year":"2003","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0056","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s00259-010-1704-x","article-title":"FDG PET\/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival","volume":"38","author":"Gerbaudo","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0057","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11604-016-0555-1","article-title":"Present and future roles of FDG\u2011PET\/CT imaging in the management of malignant pleural mesothelioma","volume":"34","author":"Kitajima","year":"2016","journal-title":"Jpn J Radiol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0058","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/icvts\/ivz303","article-title":"18F-fluorodeoxyglycose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performanc and its correlation to pathological results","volume":"30","author":"Lococo","year":"2020","journal-title":"Interact cardiovasc Thorac Surg;"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0059","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/JTO.0b013e3181c0a7ff","article-title":"Clinical value of fluorodeoxyglucose-positron emission tomography\/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: An observational pilot study","volume":"4","author":"Yildirim","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0060","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1378\/chest.114.3.713","article-title":"Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography","volume":"9","author":"Benard","year":"1998","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0061","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-2008-1039314","article-title":"The role of positron emission tomography\/computed tomography in the diagnosis of pleural diseases","volume":"57","author":"Orki","year":"2009","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0062","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3892\/etm.2012.572","article-title":"Clinical utility of 18-fluorodeoxyglucose positron emission tomography\/computed tomography in malignant pleural mesothelioma","volume":"4","author":"Terada","year":"2012","journal-title":"Exp Ther Med"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0063","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11307-009-0212-5","article-title":"Potential of dual time point FDGPET imaging in differentiating malignant from benign pleural disease","volume":"5","author":"Mavi","year":"2009","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0064","first-page":"333","article-title":"Clinical implications of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma","volume":"27","author":"Abe","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0065","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2006.06.8999","article-title":"Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F] fluorodeoxyglucose","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0066","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ejcts.2008.07.050","article-title":"Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy","volume":"34","author":"S\u00f8rensen","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0067","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/MNM.0000000000001078","article-title":"In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma","volume":"40","author":"Lopci-2","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0068","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00259-014-2960-y","article-title":"Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma","volume":"42","author":"Lopci-1","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0069","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/cam4.1182","article-title":"Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy","volume":"6","author":"Zucali","year":"2017","journal-title":"Cancer Med"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0070","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14712598.2019.1606209","article-title":"Immune checkpoint inhibition for the treatment of mesothelioma","volume":"19","author":"Nowak","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2021.04.002_bib0071","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.21037\/tlcr.2019.11.23","article-title":"Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives","volume":"9","author":"Gray","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0072","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/j.jtho.2018.08.276","article-title":"OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result","volume":"13","author":"Nowak","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0073","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","article-title":"FDG PET\/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature","volume":"46","author":"Aide","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0074","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2021.04.002_bib0075","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0076","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2967\/jnumed.111.094458","article-title":"Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3\u2032-deoxy-3\u2032-18F-fluorothymidine PET","volume":"52","author":"Kahraman","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0077","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00259-015-3165-8","article-title":"Impact of PET\/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis","volume":"43","author":"Kuhnert","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0078","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. European Association of Nuclear Medicine (EANM)","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0079","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2214\/AJR.05.0076","article-title":"Variability in mesothelioma tumor response classification","volume":"186","author":"Armato","year":"2006","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0081","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1)","volume":"13","author":"Amato","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0082","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1078-0432.CCR-09-2313","article-title":"A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters","volume":"16","author":"Nowak","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0083","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/diagnostics10080561","article-title":"Recent and Current Advances in FDG-PET Imaging within the Field of Clinical Oncology in NSCLC: A Review of the Literature","volume":"10","author":"Kaseda","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0084","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(02)08352-6","article-title":"Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomised trial","volume":"359","author":"van Tinteren","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0085","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"WHO Panel. The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0086","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1200\/JCO.2015.60.9818","article-title":"Solid predominant histologic subtype in resected stage I lung adenocarcinoma is an independent predictor of early, extrathoracic, multisite recurrence and of poor postrecurrence survival","volume":"33","author":"Ujiie","year":"2015","journal-title":"J. Clin. Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0087","doi-asserted-by":"crossref","first-page":"617","DOI":"10.21037\/tlcr.2017.09.01","article-title":"Role of PET\/CT for precision medicine in lung cancer: Perspective of the Society of Nuclear Medicine and Molecular Imaging","volume":"6","author":"Greenspan","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0088","doi-asserted-by":"crossref","first-page":"e7415","DOI":"10.1097\/MD.0000000000007415","article-title":"Retrospective analysis for the false positive diagnosis of PET-CT scan in lung cancer patients","volume":"96","author":"Feng","year":"2017","journal-title":"Medicine"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0089","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/JTO.0b013e318220c912","article-title":"Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: Results of mediastinal staging in the early lung positron emission tomography trial","volume":"6","author":"Darling","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0090","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3390\/app10051718","article-title":"PET\/CT radiomics in lung cancer: an overview","volume":"10","author":"Bianconi","year":"2020","journal-title":"Appl Sci"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0091","doi-asserted-by":"crossref","first-page":"11044","DOI":"10.1038\/srep11044","article-title":"Radiomic feature clusters and prognostic signatures specific for Lung and Head & Neck cancer","volume":"5","author":"Parmar","year":"2015","journal-title":"Sci Rep;"},{"key":"10.1053\/j.semnuclmed.2021.04.002_bib0092","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170926","article-title":"A review on radiomics and the future of theranostics for patient selection in precision medicine","volume":"91","author":"Keek","year":"2018","journal-title":"Br J Radiol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299821000180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299821000180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:59:03Z","timestamp":1762073943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299821000180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0001299821000180"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2021.04.002","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cPET\/CT Variants and Pitfalls in Lung Cancer and Mesothelioma\u201d","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2021.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}